Monday , 20 August 2018

Home » RESOURCES » INVESTING » Ultragenyx shares rise on metabolic drug study results

Ultragenyx shares rise on metabolic drug study results

Ultragenyx Pharmaceutical Inc. shares rose in the extended session Thursday after the biotech company reported positive results in a drug study meant to treat a rare metabolic disorder. Ultragenyx shares rose 3% to $51 after hours. In a late-stage clinical trial, the company said its recombinant human beta-glucuronidase treatment reduced the loss of certain complex carbohydrates needed to maintain tissue health in patients with Mucopolysaccharidosis 7.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Ultragenyx shares rise on metabolic drug study results Reviewed by on . Ultragenyx Pharmaceutical Inc. shares rose in the extended session Thursday after the biotech company reported positive results in a drug study meant to treat a Ultragenyx Pharmaceutical Inc. shares rose in the extended session Thursday after the biotech company reported positive results in a drug study meant to treat a Rating:
scroll to top